The challenge was to identify an effective, replicable, and large-scale lentiviral vector (LVV) manufacturing process, evolving from the well-established GMP 48L Nunc™ Cell Factory™ (CF) process, to meet the growing manufacturing demand – especially for market application – without affecting critical quality attributes.
Following rigorous testing, a robust, scalable, high quality and quantity process was developed for the industrial scale production of LVV for use in gene-modified cell therapy or in vivo gene therapy. Explore the details and data of the process.
